{"id":53237,"date":"2023-01-24T16:02:42","date_gmt":"2023-01-24T15:02:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synaps-dx-demonstrates-physician-burden-in-diagnosing-alzheimers-disease-value-of-highly-accurate-diagnostic-test\/"},"modified":"2023-01-24T16:02:42","modified_gmt":"2023-01-24T15:02:42","slug":"synaps-dx-demonstrates-physician-burden-in-diagnosing-alzheimers-disease-value-of-highly-accurate-diagnostic-test","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synaps-dx-demonstrates-physician-burden-in-diagnosing-alzheimers-disease-value-of-highly-accurate-diagnostic-test\/","title":{"rendered":"SYNAPS Dx Demonstrates Physician Burden in Diagnosing Alzheimer’s Disease, Value of Highly Accurate Diagnostic Test"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx<\/a> (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce the release of its white paper, \u201cClinical Study of Novel Skin Biomarker Test for Alzheimer\u2019s Disease Gains Vigorous Physician Support in Long-Sought Early Detection Breakthrough<\/a>.\u201d This document addresses findings from the clinical study of the impact on physicians who routinely perform cognitive testing and imaging to provide AD diagnoses and note several unmet needs in this process.\n<\/p>\n

<\/a><\/p>\n

\n\u201cClinicians indicate a significant need for an accurate, readily accessible and less invasive diagnostic tests to inform a definitive diagnosis of AD,\u201d says Frank Amato, CEO and president, SDx. \u201cRecent data from the Alzheimer\u2019s Association<\/a> suggests that over half of symptomatic patients are misdiagnosed for AD in the primary care setting, due in part to the lack of access to accurate diagnostic tools.\u201d<\/span>\n<\/p>\n

\nRecently released data from disease modifying treatments<\/a> suggests that drugs can slow the progression of the disease once they become available, albeit with safety considerations. When combined with the treatment burden of bi-weekly administration and cost, it is critical that patients are truly suffering from AD and not another cognitive disease, which will not be treated by AD drugs. DISCERN<\/a>\u2122<\/sup> is the only autopsy validated skin test to identify AD in patients with dementia, even in the presence of mixed dementias.\n<\/p>\n

\nThe study<\/a> found a significant level of need:\n<\/p>\n